first_img [email protected] By Damian Garde Nov. 24, 2020 Reprints Tags STAT+ Alex Hogan/STAT Log In | Learn More Good morning, one and all. Damian Garde here, filling in for Ed Silverman in the waning work hours before the big holiday. Whether you’ve chosen to visit loved ones or observe in isolation, we’d advise you to keep your decision out of the paper of record. In the meantime, here are your requisite tidbits to get the day started. As always, if you hear something interesting out there, do let us know.The European Union is planning a sweeping change in its rules governing generic drugs, Reuters reports, a move that could cut into the bottom lines of global pharmaceutical firms. The draft law, which could take effect in 2022, would crack down on firms that delay the approval of generics, limit patent protection for companies that don’t make their products available in all 27 member states, and aim to prevent drug shortages across the EU. What is it? Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED GET STARTED Pharmalittle: EU plots a crackdown on delay of generic drugs; Russia says its Covid-19 vaccine is 95% effective center_img Damian Garde Pharmalot Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. About the Author Reprints What’s included? National Biotech Reporter Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of “The Readout LOUD” podcast. @damiangarde STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.last_img